KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) EBIT Margin (2016 - 2025)

Rigel Pharmaceuticals has reported EBIT Margin over the past 15 years, most recently at 33.19% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 428.0% year-over-year to 33.19%; the TTM value through Dec 2025 reached 42.63%, up 2914.0%, while the annual FY2025 figure was 42.63%, 2914.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 33.19% at Rigel Pharmaceuticals, down from 40.91% in the prior quarter.
  • Over five years, EBIT Margin peaked at 60.09% in Q2 2025 and troughed at 156.92% in Q1 2022.
  • A 5-year average of 18.1% and a median of 7.33% in 2023 define the central range for EBIT Margin.
  • On a YoY basis, EBIT Margin climbed as much as 10900bps in 2022 and fell as far as -20846bps in 2022.
  • Year by year, EBIT Margin stood at 104.94% in 2021, then soared by 104bps to 4.05% in 2022, then skyrocketed by 35bps to 5.49% in 2023, then skyrocketed by 426bps to 28.92% in 2024, then grew by 15bps to 33.19% in 2025.
  • Business Quant data shows EBIT Margin for RIGL at 33.19% in Q4 2025, 40.91% in Q3 2025, and 60.09% in Q2 2025.